Buy Generic Urispas Online

Generic Urispas Information

Introduction

Urispas is an oral medication that contains the antispasmodic agent flavoxate hydrochloride (Flavoxate HCl). It belongs to the general health group of drugs and is primarily used to relieve symptoms of urinary tract spasms, such as urgency, frequency, and painful bladder contractions. In Hong Kong the product is supplied by licensed distributors and is regulated by the Department of Health. While the drug’s main indication is urinary‑tract related discomfort, clinicians may also prescribe it for other smooth‑muscle spasm conditions when appropriate.

What is Urispas?

Urispas is a tablet formulation that delivers a fixed dose of flavoxate HCl to the systemic circulation after oral ingestion. Flavoxate is a muscarinic antagonist that exerts a direct relaxant effect on smooth muscle of the urinary bladder, urethra, and gastrointestinal tract.

The medication is manufactured by [Manufacturer Name – if known; otherwise omitted] and is distributed in Hong Kong under the trade name Urispas. Flavoxate is marketed worldwide under several brand names, including Flavox, Helact, and Cystospasm, depending on the country. Urispas contains the same active ingredient and meets the same pharmacopeial standards as these brand‑name products, offering a comparable therapeutic option for patients who require bladder antispasmodic therapy.

How Urispas Works

Flavoxate HCl acts at the cellular level by stabilising the phosphodiesterase system and inhibiting calcium influx into smooth‑muscle cells. The resulting reduction in intracellular calcium limits contractile activity, producing a gentle relaxation of the detrusor muscle and urethral sphincter. Because flavoxate does not significantly block muscarinic receptors in the central nervous system, it produces bladder relaxation without the marked anticholinergic side effects (dry mouth, blurred vision) seen with some alternatives.

Onset of action typically occurs within 30–60 minutes after oral ingestion, and the therapeutic effect can last 4–6 hours, depending on individual metabolism and renal function. The drug is largely eliminated unchanged in the urine; the plasma half‑life is approximately 2 hours in healthy adults, allowing predictable dosing schedules.

Conditions Treated with Urispas

• Urinary bladder spasms (cystitis‑related urgency and frequency).
  In Hong Kong, urinary tract infections and overactive bladder affect a sizable proportion of the adult population, especially among women over 40. By reducing involuntary detrusor contractions, Urispas alleviates the urgency and frequency that interfere with daily activities.

• Interstitial cystitis / painful bladder syndrome.
  While not a curative therapy, flavoxate can lessen painful bladder contractions, improving quality of life for patients with chronic pelvic pain.

• Urethral spasm after catheterisation or surgery.
  Post‑operative bladder discomfort is a recognized indication; smooth‑muscle relaxation aids in painless voiding.

• Gastro‑intestinal colic (off‑label in some jurisdictions).
  The smooth‑muscle relaxant properties may provide symptomatic relief in biliary or intestinal colicky pain, though clinicians use this indication cautiously.

These uses reflect the drug’s ability to target non‑striated smooth muscle without causing profound systemic anticholinergic effects.

Who is Urispas For?

• Adults with symptomatic bladder spasms who experience urgency, frequency, or dysuria that is not adequately controlled by lifestyle measures alone.
• Patients recovering from urological procedures (e.g., catheter removal, transurethral surgery) where temporary reduction of detrusor overactivity is desirable.
• Individuals with interstitial cystitis who need adjunctive antispasmodic therapy to complement other bladder‑protective agents.
• Patients who cannot tolerate strong anticholinergic agents due to dry mouth, constipation, or cognitive concerns.

Contra‑indications include known hypersensitivity to flavoxate or any excipients, severe hepatic impairment, and acute urinary retention where relaxation of the bladder may worsen outflow obstruction. Caution is advised in the elderly, in patients with renal insufficiency, and in those taking other anticholinergic or centrally acting agents.

Risks, Side Effects, and Interactions

Common

• Dry mouth
• Mild constipation
• Dizziness or light‑headedness, especially when standing quickly (orthostatic effect)
• Nausea or mild gastrointestinal discomfort

Rare

• Visual disturbances (blurred vision)
• Skin rash or pruritus
• Palpitations or mild tachycardia

Serious

• Severe allergic reaction (angio‑edema, bronchospasm, anaphylaxis)
• Acute urinary retention in patients with underlying obstruction
• Hepatic dysfunction (elevated transaminases) – monitor in patients with pre‑existing liver disease

Drug‑drug interactions

• Concurrent use of strong anticholinergics (e.g., trihexyphenidyl, scopolamine) may increase the risk of urinary retention.
• Potent CYP3A4 inhibitors (ketoconazole, itraconazole) could modestly raise flavoxate plasma levels, though clinical significance is limited.
• Combination with other smooth‑muscle relaxants (e.g., dicyclomine) may amplify hypotensive effects.

Patients should inform their pharmacist or physician of all medicines, including over‑the‑counter products and herbal supplements, before starting Urispas.

Practical Use: Dosing, Missed Dose, Overdose

• Standard adult dosage: 200 mg (typically one tablet) taken orally three times daily after meals. The exact strength may vary; always follow the label on the packaging supplied by our online pharmacy.
• Missed dose: If a dose is forgotten, take it as soon as remembered unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and resume the regular schedule; do not double‑dose.
• Overdose: Symptoms may include pronounced dizziness, severe nausea, or intestinal cramping. If an overdose is suspected, seek immediate medical attention; supportive care (e.g., gastric lavage, activated charcoal) is the mainstay of treatment.
• Food and alcohol: Taking Urispas with meals reduces gastrointestinal irritation. Alcohol may increase dizziness; moderation is advised.
• Comorbidities: In patients with renal or hepatic impairment, dose adjustment may be necessary; a healthcare professional should assess suitability.

Buying Urispas from Our Online Pharmacy

Patients in Hong Kong who encounter limited shelf